AMPH vs PCRX

For growth investors, Pacira BioSciences, Inc.

(PCRX) is the stronger pick with 3. 6% revenue growth year-over-year, versus -1. 7% for Amphastar Pharmaceuticals, Inc. (AMPH). Amphastar Pharmaceuticals, Inc. (AMPH) offers the better valuation at 11. 8x trailing P/E (7. 4x forward), making it the more compelling value choice. Analysts rate Amphastar Pharmaceuticals, Inc. (AMPH) a "Hold" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Amphastar Pharmaceuticals, Inc.

(AMPH) is the cheapest at 11. 8x versus Pacira BioSciences, Inc. at 148. 1x. On forward P/E, Amphastar Pharmaceuticals, Inc. is actually cheaper at 7. 4x.

Over the past 5 years, Amphastar Pharmaceuticals, Inc.

(AMPH) delivered a total return of +32. 4%, compared to -62. 5% for Pacira BioSciences, Inc. (PCRX). Over 10 years, the gap is even starker: AMPH returned +103. 9% versus PCRX's -50. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pacira BioSciences, Inc.

(PCRX) is the lower-risk stock at 0. 47β versus Amphastar Pharmaceuticals, Inc. 's 1. 40β — meaning AMPH is approximately 198% more volatile than PCRX relative to the S&P 500. On balance sheet safety, Pacira BioSciences, Inc. (PCRX) carries a lower debt/equity ratio of 66% versus 83% for Amphastar Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Pacira BioSciences, Inc.

(PCRX) is pulling ahead at 3. 6% versus -1. 7% for Amphastar Pharmaceuticals, Inc. (AMPH). On earnings-per-share growth, the picture is similar: Pacira BioSciences, Inc. grew EPS 107. 4% year-over-year, compared to -33. 7% for Amphastar Pharmaceuticals, Inc.. Over a 3-year CAGR, AMPH leads at 13. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amphastar Pharmaceuticals, Inc.

(AMPH) is the more profitable company, earning 13. 6% net margin versus 1. 0% for Pacira BioSciences, Inc. — meaning it keeps 13. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMPH leads at 19. 5% versus 4. 6% for PCRX. At the gross margin level — before operating expenses — PCRX leads at 79. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Amphastar Pharmaceuticals, Inc.

(AMPH) trades at 7. 4x forward P/E versus 8. 6x for Pacira BioSciences, Inc. — 1. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PCRX: 24. 5% to $29. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Pacira BioSciences, Inc.

(PCRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 47)). Both have compounded well over 10 years (PCRX: -50. 0%, AMPH: +103. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AMPH is a small-cap deep-value stock; PCRX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.